Avadel Pharmaceuticals plc (NASDAQ:AVDL) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avadel Pharmaceuticals plc||86.41M||1.20||96.09M||-2.57||0.00|
|Protalix BioTherapeutics Inc.||37.97M||1.59||26.48M||-0.18||0.00|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Avadel Pharmaceuticals plc and Protalix BioTherapeutics Inc.
Table 2 provides Avadel Pharmaceuticals plc and Protalix BioTherapeutics Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Avadel Pharmaceuticals plc||-111.20%||-67.8%||-14.3%|
|Protalix BioTherapeutics Inc.||-69.74%||0%||0%|
Institutional and Insider Ownership
Avadel Pharmaceuticals plc and Protalix BioTherapeutics Inc. has shares held by institutional investors as follows: 54.9% and 9.7%. Insiders held roughly 0.9% of Avadel Pharmaceuticals plc’s shares. Comparatively, insiders own roughly 6.23% of Protalix BioTherapeutics Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Avadel Pharmaceuticals plc||10%||9.09%||-34.98%||-63.23%||-81.2%||-48.84%|
|Protalix BioTherapeutics Inc.||-4.24%||-6.93%||-10.57%||-11.07%||-11.09%||28.68%|
For the past year Avadel Pharmaceuticals plc had bearish trend while Protalix BioTherapeutics Inc. had bullish trend.
Protalix BioTherapeutics Inc. beats on 8 of the 10 factors Avadel Pharmaceuticals plc.
Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The companyÂ’s owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection. The company also provides Karbinal ER, an H1 receptor antagonist used to treat children with seasonal and perennial allergic rhinitis; AcipHex Sprinkle for the treatment of gastroesophageal reflux disease; Flexichamber, a collapsible holding chamber that administers aerosolized medication from pressurized metered dose inhalers; and Cefaclor for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections. In addition, its product candidates comprise sodium oxybate for narcolepsy; Hydromorphone/Trigger Lock for pain; Exenatide, a Medusa-based injectable formulation for diabetes; and LiquiTime for cough/cold. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.